Michelle Fanale, MD, is currently a Heme Oncology Global Medical Strategy Leader focusing on Lymphoma at Pfizer, having transitioned from Seagen after its acquisition in December 2023. They previously served as an Associate Professor at MD Anderson Cancer Center, where they led multidisciplinary teams in lymphoma research and clinical care. Michelle completed their Heme/Onc training at MD Anderson and their Internal Medicine training at Mayo Clinic Rochester, also holding leadership roles and engaging with key opinion leaders in the field. Their chief goals involve expanding therapies and treatment regimens for patients through clinical trials and regulatory processes.
This person is not in any teams
This person is not in any offices